. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Transl Res. 2021 Jan 2;233:92–103. doi: 10.1016/j.trsl.2020.12.009

Table 2.

Two independent SNPs in multivariate Cox hazards regression analysis with adjustment for other covariates and previous published SNPs in the PLCO Trial GWAS dataset

Variables	Category	Frequency	HR (95% CI)^a	P^a	HR (95% CI)^b	P^b
Age	Continuous	1185	1.03 (1.02–1.05)	<0.0001	1.04 (1.02–1.05)	<0.0001
Sex	Male	698	1.00		1.00
	Female	487	0.81 (0.69–0.94)	0.005	0.79 (0.68–0.93)	0.004
Smoking status	Never	115	1.00		1.00
	Current	647	1.64 (1.25–2.16)	0.0004	1.90 (1.43–2.54)	<0.0001
	Former	423	1.71 (1.27–2.29)	0.0003	1.96 (1.45–2.66)	<0.0001
Histology	AD	577	1.00		1.00
	SC	285	1.20 (0.99–1.44)	0.061	1.25 (1.03–1.51)	0.026
	Others	323	1.29 (1.08–1.53)	0.004	1.33 (1.11–1.59)	0.002
Stage	I-IIIA	655	1.00		1.00
	IIIB-IV	528	2.82 (2.32–3.42)	<0.0001	3.00 (2.46–3.66)	<0.0001
Chemotherapy	No	639	1.00		1.00
	Yes	538	0.58 (0.49–0.69)	<0.0001	0.58 (0.48–0.70)	<0.0001
Radiotherapy	No	762	1.00		1.00
	Yes	415	0.92 (0.78–1.09)	0.335	0.94 (0.79–1.11)	0.448
Surgery	No	637	1.00		1.00
	Yes	540	0.21 (0.16–0.27)	<0.0001	0.19 (0.15–0.25)	<0.0001
HBEGF rs4150236	GG/GA/AA	719/409/56	0.84 (0.74–0.95)	0.007	0.85 (0.74–0.97)	0.014
*ITPR3 rs116454384*	CC/CT/TT	807/334/37	0.85 (0.75–0.98)	0.021	0.85 (0.74–0.97)	0.020

Abbreviations: HR: hazards ratio; CI: confidence interval; SNP: single-nucleotide polymorphisms.

Stepwise analysis included age, sex, smoking status, tumor stage, histology, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3, PC4 and SNPs.

23 published SNPs were used for post-stepwise adjustment: rs779901, rs3806116, rs199731120, rs10794069, rs1732793, rs225390, rs3788142, rs73049469, rs35970494, rs225388, rs7553295, rs1279590, rs73534533, rs677844, rs4978754, rs1555195, rs11660748, rs73440898, rs13040574, rs469783, rs36071574, rs7242481, rs1049493.